LB Pharmaceuticals Inc
As of Oct 22, 2026, LB Pharmaceuticals is in Stage 3, the topping phase, now in its first week (since Oct 20, 2026). It closed at $39.42, 20.3% below its 52-week high and above its 200-day average, which is rising.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LBRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LBRX among Biotechnology31st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …31 | LBRX | Stage 3 · wk 1 | 97 | +0.6% |
LB Pharmaceuticals: quick answers
What stage is LB Pharmaceuticals in?
As of Oct 22, 2026, LB Pharmaceuticals (LBRX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 20, 2026 and is in its first week there. What the four stages mean
Is LB Pharmaceuticals in an uptrend?
Its uptrend has stalled. LB Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 23.2% above its 200-day average, which is rising.
How far is LB Pharmaceuticals from its 52-week high?
LB Pharmaceuticals closed at $39.42 on Oct 22, 2026, 20.3% below its 52-week high of $49.48. Its 52-week low is $14.61.
How has LB Pharmaceuticals performed over the past year?
As of Oct 22, 2026, LB Pharmaceuticals is up 146.4% over the past year and up 92.9% so far in 2026.
Which sector and industry is LB Pharmaceuticals in?
LB Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.